

disclosure under subsection (b)(4) of the Freedom of Information Act (5 U.S.C. 552(b)(4)). However, the confidentiality status of the survey would be determined on a case-by-case basis, when the specific questions to be asked on each particular survey are formulated but before respondents are contacted. Respondents will be informed of the confidentiality status of that particular survey, each time the survey would be conducted.

**Abstract:** The 2023 requests qualitative and limited quantitative information about liability management, the provision of financial services, and the functioning of key financial markets from a selection of up to sixty large commercial banks (or, if appropriate, from other depository institutions or major financial market participants). Responses are obtained from a senior officer at each participating institution through a telephone interview. The survey is conducted when major informational needs arise and cannot be met from existing data sources. The survey does not have a fixed set of questions; each survey consists of a limited number of questions directed at topics of timely interest. The survey helps pinpoint developing trends in bank funding practices, enabling the Federal Reserve to distinguish these trends from transitory phenomena.

**Current Actions:** On February 26, 2009, the Federal Reserve published a notice in the **Federal Register** (74 FR 8794) requesting public comment for 60 days on the extension, without revision, of the Senior Financial Officer Survey. The comment period for this notice expired on April 27, 2009. No comments were received.

3. **Report titles:** Quarterly Report of Interest Rates on Selected Direct Consumer Installment Loans and Quarterly Report of Credit Card Plans.  
**Agency form numbers:** FR 2835 and FR 2835a.  
**OMB control number:** 7100-0085.  
**Frequency:** Quarterly.  
**Reporters:** Commercial banks.  
**Annual reporting hours:** FR 2835, 132 hours; and FR 2835a, 100 hours.  
**Estimated average hours per response:** FR 2835, 13.2 minutes; and FR 2835a, 30 minutes.

**Number of respondents:** FR 2835, 150; and FR 2835a, 50.

Small businesses are not affected.  
**General description of report:** These information collections are voluntary (12 U.S.C. 248(a)(2)). The FR 2835a individual respondent data are given confidential treatment (5 U.S.C. 552(b)(4)), the FR 2835 data however, is not given confidential treatment.

**Abstract:** The FR 2835 collects information from a sample of commercial banks on interest rates charged on loans for new vehicles and loans for other consumer goods and personal expenses. The FR 2835a collects information on two measures of credit card interest rates from a sample of commercial banks with \$1 billion or more in credit card receivables and a representative of smaller issuers.

**Current Actions:** On February 26, 2009, the Federal Reserve published a notice in the **Federal Register** (74 FR 8794) requesting public comment for 60 days on the extension, without revision, of the Senior Financial Officer Survey. The comment period for this notice expired on April 27, 2009. The Federal Reserve received one comment from a federal agency describing its use of the FR 2835 and FR 2835a data to prepare

monthly, quarterly, and annual estimates of personal interest payments, a component of personal outlays in the national income and product accounts.

Board of Governors of the Federal Reserve System, May 11, 2009.

**Jennifer J. Johnson,**  
*Secretary of the Board.*  
 [FR Doc. E9-11275 Filed 5-13-09; 8:45 am]  
**BILLING CODE 6210-01-P**

**FEDERAL TRADE COMMISSION**

**Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules**

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entities
<b>Transactions Granted Early Termination—04/20/2009</b>			
20090390 .....	Sterling Capital Partners III, L.P .....	Nova Records Management, LLC .....	Capital Records Management, Incorporated; Garden State Consulting, LLC; Nova Records, Inc.; Nova Records, LLC; Records Management Corporation; Release of Information Solutions, Inc.
<b>Transactions Granted Early Termination—04/21/2009</b>			
20090380 .....	Deloitte LLP .....	BearingPoint, Inc .....	BearingPoint, Inc.
<b>Transactions Granted Early Termination—04/22/2009</b>			
20090378 .....	Sanofi-Aventis .....	BiPar Sciences, Inc .....	BiPar Sciences, Inc.
20090386 .....	James R. Leininger, M.D.	BioNumerik Pharmaceuticals, Inc .....	BioNumerik Pharmaceuticals, Inc.
<b>Transactions Granted Early Termination—04/24/2009</b>			
20090393 .....	Williams Companies, Inc .....	Atlas Pipeline Partners, L.P .....	Atlas Pipeline McKean, LLC; Atlas Pipeline New York, LLC.

Trans #	Acquiring	Acquired	Entities
20090396 .....	Advent-Kong Blocker Corp .....	Fifth Third Bancorp .....	Fifth Third Processing Solutions, LLC.
20090400 .....	Spectra Energy Corp. ....	Atlas Pipeline Partners, L.P .....	Atlas Pipeline Pennsylvania, LLC; Laurel Mountain Midstream Operating, LLC; Atlas Arkansas Pipeline LLC; Mid-Continent Arkansas Pipeline, LLC; NOARK PIPELINE System, Limited Partnership; Ozark Gas Gathering, LLC; Ozark Gas Transmission, LLC.
20090407 .....	Rosa Anna Magno Garavoglia .....	Pemod Ricard S.A .....	Austin Nichols & Co., Inc.; Pemod Ricard USA, LLC.

**Transactions Granted Early Termination—04/27/2009**

20090254 .....	Big Rivers Electric Corporation .....	E.ON AG .....	LG&E Energy Marketing Inc.; Western Kentucky Energy Corp.
20090408 .....	Stichting Pensioenfonds ABP .....	Hammerstein Properties LLC .....	Hammerstein Properties LLC.
20090414 .....	Stichting Pensioenfonds ABP .....	Richard Rodgers Family Trust .....	Richard Rodgers Family Trust

**Transactions Granted Early Termination—04/28/2009**

20090368 .....	Community Health Systems, Inc .....	Wyoming Valley Health Care System, Inc.	Wyoming Valley Health Care System, Inc.
----------------	-------------------------------------	---	---

**Transactions Granted Early Termination—04/29/2009**

20090329 .....	INS, Inc. ....	VenSign, Inc .....	VenSign, Inc.
20090367 .....	National Oilwell Varco, Inc .....	Lee Barberito .....	Dynamic Drilling Fluids, LLP; Spirit Completion Fluids, Ltd.; Spirit Drilling Fluids, Ltd.; Spirit Drilling Fluids Sub, LLC; Spirit Minerals, L.P.
20090413 .....	Hudson Clean Energy Partners, L.P	Calisolar Inc .....	Calisolar Inc.

**Transactions Granted Early Termination—05/01/2009**

20090415 .....	MatlinPatterson Global Opportunities Partners III L.P.	D.E. Shaw Composite International Fund.	Foamex International, Inc.
20090420 .....	GS Capital Partners VI, L.P .....	Global Hyatt Corporation .....	Global Hyatt Corporation.

**FOR FURTHER INFORMATION CONTACT:**  
Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By Direction of the Commission.  
**Donald S. Clark,**  
Secretary.

[FR Doc. E9-11249 Filed 5-13-09; 8:45 am]  
BILLING CODE 6750-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society**

Pursuant to Public Law 92-463, notice is hereby given of the nineteenth meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health

Service. The meeting will be held from 8:30 a.m. to approximately 5 p.m. on Thursday, June 11, 2009, and from 8:30 a.m. to approximately 3 p.m. on Friday, June 12, 2009, at the Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201. The meeting will be open to the public with attendance limited to space available. The meeting also will be Web cast.

At the meeting, the Committee will continue its exploration of genetics and the future health care system by hearing presentations on anticipated changes in health care and the role genetics and genomics can play in achieving an effective, affordable, and equitable health care system. In addition, the Committee will discuss its work on genetics education and training and consider a draft report on direct-to-consumer genomic services. Updates will be provided as well on regulations implementing the Genetic Information Nondiscrimination Act and on the Committee's Public Consultation Draft Report on Gene Patents and Licensing

**Practices and Their Impact on Patient Access to Genetic Tests.**

As always, the Committee welcomes hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Individuals who would like to provide public comment should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at [carrs@od.nih.gov](mailto:carrs@od.nih.gov). The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, is also asked to contact the Executive Secretary.

Under authority of 42 U.S.C. 217a, section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic and genomic technologies and, as warranted, to provide advice on these